|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
2,250,000,000 |
Market
Cap: |
93.44(B) |
Last
Volume: |
20,542,542 |
Avg
Vol: |
12,077,193 |
52
Week Range: |
$40.25 - $64.73 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 100 |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 97 |
Guru Rank Value : 8.6 |
Guru Occurances : 3 |
|
|
|
|
|
|
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
13,571 |
13,571 |
Total Buy Value |
$0 |
$0 |
$672,994 |
$672,994 |
Total People Bought |
0 |
0 |
2 |
2 |
Total Buy Transactions |
0 |
0 |
3 |
3 |
Total Shares Sold |
0 |
0 |
18,718 |
616,397 |
Total Sell Value |
$0 |
$0 |
$1,146,397 |
$44,859,834 |
Total People Sold |
0 |
0 |
2 |
5 |
Total Sell Transactions |
0 |
0 |
2 |
11 |
End Date |
2024-03-31 |
2023-12-29 |
2023-06-30 |
2022-06-30 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bancroft Charles A |
EVP & Chief Financial Officer |
|
2017-03-10 |
4 |
D |
$58.32 |
$2,333,267 |
D/D |
(40,008) |
261,369 |
|
- |
|
Bancroft Charles A |
EVP & Chief Financial Officer |
|
2017-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
87,324 |
289,293 |
|
- |
|
Bancroft Charles A |
EVP & Chief Financial Officer |
|
2017-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,659) |
229,647 |
|
- |
|
Bancroft Charles A |
EVP & Chief Financial Officer |
|
2017-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
3,196 |
224,650 |
|
- |
|
Andreotti Lamberto |
Director |
|
2017-03-10 |
4 |
D |
$58.32 |
$3,323,832 |
D/D |
(56,993) |
1,003,112 |
|
- |
|
Andreotti Lamberto |
Director |
|
2017-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
102,174 |
1,060,105 |
|
- |
|
Nielsen Anne |
Chief Compliance & Ethics Off |
|
2017-03-10 |
4 |
D |
$58.32 |
$316,911 |
D/D |
(5,434) |
37,217 |
|
- |
|
Nielsen Anne |
Chief Compliance & Ethics Off |
|
2017-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,696 |
41,215 |
|
- |
|
Nielsen Anne |
Chief Compliance & Ethics Off |
|
2017-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(264) |
31,542 |
|
- |
|
Nielsen Anne |
Chief Compliance & Ethics Off |
|
2017-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
346 |
30,619 |
|
- |
|
Cuss Francis M |
EVP & CSO |
|
2017-03-10 |
4 |
D |
$58.32 |
$2,009,241 |
D/D |
(34,452) |
321,906 |
|
- |
|
Cuss Francis M |
EVP & CSO |
|
2017-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
66,726 |
346,770 |
|
- |
|
Cuss Francis M |
EVP & CSO |
|
2017-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,484) |
301,379 |
|
- |
|
Cuss Francis M |
EVP & CSO |
|
2017-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,384 |
297,113 |
|
- |
|
Schmukler Louis S |
Pres., Global Mfg. & Supply |
|
2017-03-10 |
4 |
D |
$58.32 |
$842,841 |
D/D |
(14,452) |
41,483 |
|
- |
|
Schmukler Louis S |
Pres., Global Mfg. & Supply |
|
2017-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,271 |
51,898 |
|
- |
|
Schmukler Louis S |
Pres., Global Mfg. & Supply |
|
2017-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(670) |
29,787 |
|
- |
|
Schmukler Louis S |
Pres., Global Mfg. & Supply |
|
2017-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,363 |
27,378 |
|
- |
|
Leung Sandra |
EVP, General Counsel |
|
2017-03-10 |
4 |
D |
$58.32 |
$2,011,748 |
D/D |
(34,495) |
427,791 |
|
- |
|
Leung Sandra |
EVP, General Counsel |
|
2017-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
65,424 |
451,862 |
|
- |
|
Leung Sandra |
EVP, General Counsel |
|
2017-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,227) |
407,330 |
|
- |
|
Leung Sandra |
EVP, General Counsel |
|
2017-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,431 |
404,322 |
|
- |
|
Blin Emmanuel |
SVP, Chief Strategy Officer |
|
2017-03-10 |
4 |
D |
$58.32 |
$322,510 |
D/D |
(5,530) |
20,138 |
|
- |
|
Blin Emmanuel |
SVP, Chief Strategy Officer |
|
2017-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,275 |
23,690 |
|
- |
|
Blin Emmanuel |
SVP, Chief Strategy Officer |
|
2017-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(379) |
15,551 |
|
- |
|
953 Records found
|
|
Page 23 of 39 |
|
|